Document is current
Any future updates will be listed below
-
Authors
Kramer, C. J. H.
van Wijk, L. M.
Ruano, D.
Gelpke-Vermeulen, S.
van der Tuin, K.
van der Stoep, N.
van Wezel, T. https://orcid.org/0000-0001-5773-7730
Wesseling, J. https://orcid.org/0000-0002-8940-2676
Vallon-Christersson, J. https://orcid.org/0000-0002-2195-0385
Smit, V. T. H. B. M.
Cohen, D.
Vrieling, H.
Staaf, J. https://orcid.org/0000-0001-5254-5115
Bosse, T. https://orcid.org/0000-0002-6881-8437
van Asperen, C. J. https://orcid.org/0000-0002-1436-7650
Vreeswijk, M. P. G.
-
Funding
Funding for this research was provided by:
AstraZeneca (ESR-21-21497)
KWF Kankerbestrijding (12995)
- License Information
-
More Information
Article History
Received: 12 July 2024
Revised: 18 May 2025
Accepted: 16 July 2025
First Online: 23 August 2025
Competing interests
: The authors declare no competing interests.
: The SCAN-B study (exploration phase) (ClinicalTrials.gov ID NCT02306096) was approved by the Regional Ethical Review Board in Lund, Sweden (applicable registration numbers 2009/658, 2015/277, 2016/742, 2018/267 and 2019/01252) [, ]. All patients provided written informed consent prior to enrollment. For the feasibility cohort, the study design was approved by the medical ethics committee of the Leiden University Medical Center (N20.183). The study was performed in accordance with the Declaration of Helsinki.
